About this event
- Date and time Fri 12 Dec 2025 from 9:00am to 4:30pm
- Location Royal Society of Medicine
A joint meeting between Prostate Cancer UK, The Royal Marsden Hospital, the Institute of Cancer Research, and the Royal Society of Medicine.
This high-profile conference brings together national and international experts to share the latest data on the use of genetic information in the prostate cancer care pathway. Prostate cancer is the most common cancer in men in the UK, yet many are diagnosed at an advanced stage. A key clinical challenge remains: identifying men likely to develop aggressive disease early, while avoiding over-diagnosis and overtreatment of indolent cases. Research shows that around half of prostate cancers have a genetic cause, driven by a combination of common and rare germline variants. With genomics increasingly embedded in healthcare, understanding its role in risk prediction, targeted screening, and personalised treatment is essential for every clinician working in prostate cancer care.
Why Attend?
- Understand the role of genomics for the multidisciplinary prostate cancer care team.
- Learn when and how genetic testing is indicated in the management pathway.
- Hear the latest global research on identifying men at increased genetic risk.
- Review current testing guidelines and targeted screening strategies.
- Explore clinical applications of genomics in treatment planning and patient follow-up.
- Listen to a real patient story on the lived experience of genetic testing and its impact.
- Earn CPD credits while enhancing your clinical and research knowledge.
Programme Highlights
- Global updates on genetic predisposition to prostate cancer.
- Evidence for targeted prostate cancer screening in high-risk populations.
- The application of genomics in diagnosis, prognosis, and treatment selection.
- The patient journey through genetic testing – challenges and benefits.
- Discussion of guidelines, policy implications, and opportunities for implementation in the NHS.
Who Should Attend?
This event is designed for medical and academic professionals involved in prostate cancer research, diagnosis, and care, including:
- Urology consultants and trainees.
- Oncologists and oncology trainees.
- Specialist nurses.
- Researchers and geneticists.
- Healthcare policy makers and stakeholders.
- Representatives from patient organisations and charities.
Overall Aim
- To equip healthcare professionals with the latest evidence on genetic predisposition to prostate cancer, targeted screening for early detection, and the clinical application of genomics throughout the patient care pathway.
Learning Outcomes
By attending, you will:
- Expand knowledge of the genetic and genomic factors contributing to prostate cancer risk.
- Understand the latest evidence on targeted screening in higher risk groups.
- Recognise the current and potential uses of genomics in the prostate cancer care pathway.
- Appreciate the patient perspective on genetic testing and its impact on care and quality of life.
Don’t miss this opportunity to hear from leading voices in urology, oncology, genetic research, and patient advocacy — and to be part of shaping the genomics-informed future of prostate cancer care.
Register now to secure your place at this essential meeting.
Follow us on:
Facebook
Instagram
LinkedIn
Twitter
YouTube
We would like to thank our sponsors Source BioScience and Veritas for their support of this event. The companies listed have had no influence or input into the main scientific programme, content or organisation of this meeting.
Agenda
View the programme
Registration, tea and coffee
Welcome and introduction
Professor Ros Eeles, Professor of Oncogenetics, The Institute of Cancer Research & Royal Marsden NHS Foundation Trust UK
The landscape of genetic variation in the germline
Chair: Professor Ros Eeles
Genetic predisposition to prostate cancer – rare and common genetic variation
Professor Ros Eeles
Somatic alterations in prostate cancer – the Pan Prostate Cancer Group international initiative
Professor Colin Cooper, Professor of Cancer Genetics, The University of East Anglia
Tea and coffee break
Applications to targeted screening in higher risk groups
Chair: Dr Matthew Hobbs, Director of Research, Prostate Cancer UK
Targeted screening in those with higher risk rare variants – the IMPACT suite of studies
Dr Elizabeth Bancroft, Nurse Consultant, Royal Marsden NHS Foundation Trust
The Barcode 1 study – polygenic risk for stratified screening
Professor Ros Eeles
TRANSFORM - how the UK’s once-in-a-generation screening trial will help us understand risk of prostate cancer and screening strategies
Dr Matthew Hobbs, Director of Research, Prostate Cancer UK
Lunch
Latest data in tumour molecular analyses and systemic targeted treatment of advanced disease based on molecular results
Chair: Professor Ros Eeles
How to order genetic testing (somatic and germline) and the UK national testing directory
Dr Terri McVeigh, Consultant in Cancer Genetics Royal Marsden NHS Foundation Trust UK
How to manage patients with genetic alterations – the latest data on targeted treatments
Dr Alison Reid, Consultant Medical Oncologist, Royal Marsden NHS Foundation Trust UK
Tea and coffee break
Areas of uncertainty in the molecular tests for patients
Chair: Professor Roger Kirby, Past President, Royal Society of Medicine
The Stockholm 3 test for screening – should we be using it?
Professor Henrik Gronberg, Professor of Medical Oncology, Karolinska Institutet, Sweden
Should I be ordering the Decipher, Oncotype Dx and Prolaris tests on my patients?
Dr Tyler Seibert, Assistant Professor in Radiation Oncology, University of California, San Diego
Patient Story
Tony McHale, Writer (Previous Writer and Producer of Holby City)
Closing remarks
Professor Roger Kirby, Past President, Royal Society of Medicine
Sponsors
Location
Royal Society of Medicine, 1 Wimpole St, Marylebone, London, W1G 0AE, United Kingdom
Registration for this event will close on 11 December 2025 at 1:00am (GMT). Late registrations will not be accepted.
The agenda is subject to change at any time.
All views expressed at this event are of the speakers themselves and not of the Royal Society of Medicine, nor the speaker's organisations.
We are only able to share presentations that we have received permission to share. This is at the presenter and the RSM’s discretion.
